Baricitinib 4 MG

WITHDRAWN · PHASE3 · Post-Acute COVID-19 Syndrome

This submission for the pilot study has been withdrawn as the full trial opened under a different NCT number before participants enrolled in the pilot.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.